Local News

• Expression Analysis (EA) purchases its first Illumina Genome Analyzer  Illumina announced that Expression Analysis, an Illumina certified service provider (CSPro) and leading supplier of genotyping, gene expression, and resequencing services for genetic research, purchased its first Genome Analyzer.
  Illumina January 08, 2009  
• Impax confirms patent challenge relating to Amrix (R) extended-release capsules  IMPAX Laboratories announced that Eurand, Cephalon, and Anesta AG have filed suit for patent infringement based on the Company's submission of Abbreviated New Drug Application for cyclobenzaprine hydrochloride extended release capsules (15 and 30 mg), generic of Amrix(R), to the FDA.
  IMPAX Laboratories, Inc. January 08, 2009  
• Howard Feldman joins Bristol-Myers Squibb as vice president and therapeutic area head  Bristol-Myers Squibb announced that Dr. Howard Feldman has joined the company's Research and Development organization as vice president and therapeutic area head, Global Clinical Research, Neuroscience.
  Bristol-Myers Squibb Company January 08, 2009  
• Genomic Health announces management changes and new responsibilities  Genomic Health announced the appointment of Kimberly J. Popovits as chief executive officer. Formerly president and chief operating officer, Popovits is now the president and CEO of Genomic Health.
  Genomic Health, Inc. January 08, 2009  
• Cell Therapeutics receives $7.5 million under joint venture agreement with Spectrum  Cell Therapeutics announced that they received $7.5 million pursuant to the joint venture transaction with Spectrum Pharmaceuticals to commercialize and develop Zevalin(R) in the United States.
  Cell Therapeutics, Inc. January 08, 2009  
• Liquidia, Abbott team up to target cancer  One of the biggest challenges of cancer treatment is delivering drugs in a way that kills the bad cells without doing too much damage to healthy cells. The CEO of Liquidia Technologies hopes that a deal announced between his company and Abbott Laboratories will help to address that problem.
  Triangle Business Journal January 07, 2009  Jeff Drew
• Positive step for drug from engineered goat  In a surprise move, it seems likely the first genetically engineered animal approved for commercial use won't be a fast-growing salmon, as was expected, but a goat that produces an anti-clotting drug in its milk.
  USATODAY January 07, 2009  Elizabeth Weise
• FDA issues a Complete Response Letter for Lilly's olanzapine LAI  Eli Lilly and Company announced that it received a complete response letter from the U.S. Food and Drug Administration (FDA) for olanzapine long-acting injection (LAI) for acute and maintenance treatment of schizophrenia in adults.
  Eli Lilly and Company January 07, 2009  
• CV Technologies announces temporary management cease trade order  CV Technologies announces that a temporary management cease trade order has been issued by the Ontario Securities Commission in respect of the Ontario-resident persons named in the Order.
  CV Technologies Inc. January 07, 2009  
• Volcano announces closing of Axsun Technologies acquisition  Volcano Corporation said that it has closed its previously announced acquisition of Axsun Technologies. Axsun is a leading developer and manufacturer of lasers and optical engines used in medical Optical Coherence Tomography (OCT) imaging systems.
  Volcano Corporation January 07, 2009  

   (next 10 articles)